Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry

Lenacapavir, the first-in-class capsid inhibitor, targets multiple stages of the HIV lifecycle, thereby inhibiting viral replication.1 Thanks to its new mechanism of action, lenacapavir is approved for use in people with HIV (PWH) who have limited treatment options.2,3 While its efficacy has been demonstrated in clinical trials,4–6 real-world data in PWH with extensive treatment experience remain scarce. We aimed to evaluate the durability and viro-immunological outcomes of lenacapavir-containing regimens in viremic PWH harbouring four-class drug-resistant (4DR) strains

Authors

Institutions

Publication Details

Journal
Journal of Antimicrobial Chemotherapy
Published
2025-11-10
DOI
https://doi.org/10.1093/jac/dkaf415
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry

Davide Laurenda, Federica Malerba, Daniela Valenti, Silvia Lamonica et al.
Journal of Antimicrobial Chemotherapy
HIV/AIDS drug development and treatment
article

Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry

Davide Laurenda, Federica Malerba, Daniela Valenti, Silvia Lamonica, Maurizio Zazzi, Antonio Di Biagio, Camilla Muccini, Riccardo Lolatto, Stefania Zanussi, Marcello Tavio, Marcello Feasi, Roberta Gagliardini, Tiziana Formenti, Spinello Antinori, Elisa Mariabelli, Maria Mazzitelli, Massimo Puoti, Valentina Da Ros, Simoncini Elena, Andrea Galli, Tommaso Clemente, Andrea De Vito, Elisa Garlassi, Roberto Gulminetti, Tiziana Mulas, Manuela Colafigli, Rachele Pincino, Loredana Sarmati, Maria Teresa Demitri, Laura Comi, Marcello Trizzino, Giulia Nardini, Martina Bottanelli, Chiara Fornabaio, Maria Mercedes Santoro, Mirko Compagno, Diletta Laccabue, Massimiliano Fabbiani, Stefano Nardi, Anna Maria Cattelan, Elio Manzillo, Silvia Fantino, Alessandra Ferrari, Nicolò Capra, Andrea Calcagno, Adriana Cervo, Matteo Bassetti, Benedetto Maurizio Celesia, Vincenzo Olivadese, Romina Corsini, Flavia Balena, Pierluigi Viale, Antonio Sarà, Daniela Francisci, Davide Minisci, Paolo Fusco, Elisa Fronti, Elisabetta Schiaroli, Giuseppe Vittorio De Socio, Filippo Lagi, Silvia Magnani, Stefano Rusconi, Elisabetta Carini, Emanuele Pontali, Vincenzo Spagnuolo, Antonio Cascio, Federico D’Amico, Carmen Giarratana, C Abeli, Sabrina Bagaglio, Francesco Castelli, Alessio Bellucci, Ilaria Rancan, Francesca Panza, Silvia Pontiggia, Barbara Menzaghi, Marisa Fusto, Mario Tumbarello, Marta Fiscon, Pierluigi Francesco Salvo, Giulia Marchetti, Guido Calleri, Giordano Madeddu, Layla Pagnucco, Maddalena Farinazzo, Roberta Gagliardini, Francesco Bassani, Antonella Gallicchio, Liana Bevilacqua, Annalisa Saracino, Federica Carli, Cristina Mussini, Stefania Piconi, Teresa Santantonio, Sergio Lo Caputo, Ornella Schioppa, Riccardo Riccardi, Cinzia Bassoli, Bruno Cacopardo, Silvia Cretella, Cristina Moioli, Simone Rossetto, Francesco Saladini, Rebecka Papaioannu Borjesson, A Narducci, Michele Salvatore Paternò Raddusa, Sassi Serena, Angelo Pan, Cecilia Costa, Alessandro Bartoloni, Vincenzo Malagnino, Paola Brambilla, Giuseppe Gullo, Maria Mercedes Santoro, Antonella Castagna, Girolamo Piromalli, Stefano Bonora, Simona Di Giambenedetto, Carlo Torti, Giovanni Di Perri, Giovanni Cenderello, Sergio Ferrara, Paola Corsi, Sabrina Blanchi, Marta Grauso, Giancarlo Orofino, Alessandra Mataloni Paggi, Anna Maria Cattelan, Lidia Gazzola, Fabiana Trionfo Fineo, Golnaz Torkjazi, Simona Mongiardi, Valsecchi Giada, Trevisan Sasha
article en

Abstract

Lenacapavir, the first-in-class capsid inhibitor, targets multiple stages of the HIV lifecycle, thereby inhibiting viral replication.1 Thanks to its new mechanism of action, lenacapavir is approved for use in people with HIV (PWH) who have limited treatment options.2,3 While its efficacy has been demonstrated in clinical trials,4–6 real-world data in PWH with extensive treatment experience remain scarce. We aimed to evaluate the durability and viro-immunological outcomes of lenacapavir-containing regimens in viremic PWH harbouring four-class drug-resistant (4DR) strains

Journal of Antimicrobial ChemotherapyVol. 81(1)
University of Rome Tor Vergata (IT), University of Verona (IT), University of Parma (IT), University of Padua (IT), Vita-Salute San Raffaele University (IT), University of Perugia (IT), Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT), Azienda Ospedaliera Universitaria Integrata Verona (IT), Torino e-district (IT), Ospedale di Parma (IT), Hospital for Tropical Diseases (VN)
Openalex Percentile: Top 61%
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.